Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

MRNA Stock Outperforms Industry, Sector & S&P 500 Encouraging Upcoming Launches Moderna (MRNA) has risen 22.1% in the year-to-date period against the industry's 2.7% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the company are currently trading above its 200-day moving average. Image Source: Zacks Investment Research Despite registering a significant fall in top-line due to lower COVID-19 vaccine sales, Moderna's shares continue to soar this year on the ...